Definitive Healthcare Corp

Definitive Healthcare Corp. engages in the provision of healthcare commercial intelligence. Its solution offers information on healthcare providers and their activities to help the customers optimize from product development to go-to-market planning, sales, and marketing execution. The company was founded by Jason Kranzt in February 2011 and is headquartered in Framingham, MA.

Earnings data Q1 2024

Definitive Healthcare reports robust Q1 performance amidst macroeconomic challenges

DH (DH) Q1 2023 showcased strong financial performance and strategic wins in target markets, despite challenges posed by the macroeconomic environment. The company's focus on M&A, product innovation, and internal improvements positions it well for future growth and value delivery.

DH reports strong Q2 earnings, eyes healthcare analytics growth

DH's Q2 performance reflects growth and strategic wins, despite workforce reduction and challenges in enterprise customer accounts. The acquisition of Populi and focus on pipeline generation present opportunities for future growth.

DH reports strong Q3 earnings and focuses on minimizing churn

DH's Q3 performance exceeded expectations, but challenges with budget scrutiny and churn persist. The company's focus on minimizing churn and driving new business and renewals in Q4 presents opportunities for growth. Despite tough market conditions, DH remains optimistic about improving results in the next two quarters.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Partnership offers solution to streamline engagement between pharmaceutical companies and KOLs to help increase the value of the clinical collaborations and conversations Partnership offers solution to streamline engagement between pharmaceutical companies and KOLs to help increase the value of the clinical collaborations and conversations

VML and Definitive Healthcare announce partnership to transform key opinion leader management

Definitive Healthcare stock is recommended as a buy due to strong long-term growth prospects and potential for margin expansion. Recent results show revenue growth in line with estimates and improved profitability, despite concerns about net dollar retention and customer churn. Management guidance supports a turnaround in FY25, with indicators of healthy organic demand and potential for growth acceleration.

Definitive Healthcare: Reiterate Buy Rating As I Expect Growth To Recover In FY25

FRAMINGHAM, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare  (Nasdaq:  DH ), an industry leader in healthcare commercial intelligence, today announced that it has been named one of the Boston Business Journal's Middle Market Leaders for 2024, a ranking of the 50 highest growth companies in Massachusetts. This marks the second year in a row that Definitive Healthcare has won this award.

Definitive Healthcare earns 2024 Middle Market Leader Award from Boston Business Journal

Definitive Healthcare Corp. (DH) Q4 2023 Earnings Call Transcript

Fourth quarter revenue grew 9% year-over-year to $65.9 million Full year 2023 revenue grew 13% year-over-year to $251.4 million  FRAMINGHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2023.

Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2023

FRAMINGHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2023, on Wednesday, February 28, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

Definitive Healthcare Announces Timing of Its Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast

After losing some value lately, a hammer chart pattern has been formed for Definitive Healthcare Corp. (DH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Definitive Healthcare Corp. (DH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Jason Krantz, Founder and Executive Chairman, to Serve as Interim CEO Company Reaffirms Fourth Quarter 2023 Guidance and Issues Preliminary Guidance for 2024 FRAMINGHAM, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH) (the “Company”), an industry leader in healthcare commercial intelligence, today announced that Robert Musslewhite has stepped down as Chief Executive Officer and as a member of the Board of Directors to transition to a new phase of leadership for the Company.

Definitive Healthcare Announces CEO Transition

Strengthening fundamentals: Definitive Healthcare shows steady revenue growth at 10% and expanding adjusted EBITDA margins. CRPO growth is slowing to a controlled rate and stabilizing, which indicates the end of client churn that took place over past 2 years. Valuation outlook: Fair price potential around $9.0, signaling a 25% upside from current $7.18.

Definitive Healthcare: Undervalued Vs. Peers Given Revenue Growth And Margin Expansion

Definitive Healthcare Corp. (DH) Q3 2023 Earnings Call Transcript

FRAMINGHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of Carrie Lazorchak as Definitive Healthcare's new Chief Revenue Officer, the Human Capital Management and Compensation Committee (the “Committee”) of Definitive Healthcare's Board of Directors granted Ms. Lazorchak an inducement award consisting of 385,695 time-based restricted stock units (“RSUs”) effective November 1, 2023. This award was individually negotiated and was granted as an inducement material to Ms. Lazorchak's commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).

Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

Definitive Healthcare Corp. (DH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Definitive Healthcare Corp. (DH) Soars 7.1%: Is Further Upside Left in the Stock?

FRAMINGHAM, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its third quarter ended September 30, 2023, on Thursday, November 2, 2023 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

Definitive Healthcare Announces Timing of Its Third Quarter 2023 Financial Results Conference Call and Webcast

FRAMINGHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that Carrie Lazorchak has been named Chief Revenue Officer, effective November 1, 2023.

Definitive Healthcare Names Carrie Lazorchak as Chief Revenue Officer

DH Q2 results were solid, with revenue in line and adjusted EBITDA slightly ahead. The company's near-term outlook is uncertain due to macroeconomic factors and extended sales cycles. Despite short-term challenges, the company's proprietary data competitive advantage positions it for long-term growth.

Definitive Healthcare: Fundamentals Remain Sound But Stock Sentiment Is Bad

FRAMINGHAM, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced two changes to its Board of Directors. On September 6, 2023, Scott Stephenson, the former Chief Executive Officer of Verisk Analytics, joined the Board of Directors and the nominating and corporate governance committee of the Board, while Chris Mitchell, managing director of Spectrum Equity, stepped down from the Board of Directors.

Definitive Healthcare Welcomes Scott Stephenson to Board of Directors

FRAMINGHAM, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with Definitive Healthcare's acquisition of Populi, Inc. (“Populi”), effective September 6, 2023, the Human Capital Management and Compensation Committee (the “Committee”) of Definitive Healthcare's Board of Directors granted inducement awards consisting of 551,758 performance-based restricted stock units (“PSUs”) and 274,728 time-based restricted stock units (“RSUs”) to 30 former employees of Populi. These awards include 137,363 PSUs (the “Moschella PSUs”) and 201,467 RSUs (the “Moschella RSUs”) granted to William Moschella, as well as 45,788 PSUs (the “Salmon PSUs”) and 73,261 RSUs (the “Salmon RSUs”) granted to Nathan Salmon, which were individually negotiated. The awards were granted as an inducement material to such individuals' commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).

Definitive Healthcare Corp. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FRAMINGHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Executive Officer, Robert Musslewhite, and its Chief Financial Officer, Rick Booth, will present at the Morgan Stanley 21st Annual Global Healthcare Conference.

Definitive Healthcare to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ: DH). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Definitive Healthcare Corp. - DH

Definitive Healthcare Corp. (NASDAQ:DH ) Q2 2023 Results Conference Call August 14, 2023 5:00 PM ET Company Participants Matt Ruderman - Chief Legal Officer Robert Musslewhite - Chief Executive Officer Jason Krantz - Founder and Executive Chairman Rick Booth - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Matt Shea - Needham & Company Brian Peterson - Raymond James Allen Lutz - Bank of America David Grossman - Stifel Jonathan Yong - Credit Suisse George Hill - Deutsche Bank Operator Welcome to the Definitive Healthcare Q2 2023 Earnings Call. Our host for today's call is Robert Musslewhite.

Definitive Healthcare Corp. (DH) Q2 2023 Earnings Call Transcript

Acquisition broadens Definitive Healthcare's suite of healthcare commercial intelligence solutions with new data, analytics, and visualization tools tailor-built for the provider market Acquisition broadens Definitive Healthcare's suite of healthcare commercial intelligence solutions with new data, analytics, and visualization tools tailor-built for the provider market

Definitive Healthcare acquires Populi

FRAMINGHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30, 2023.

Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2023

Neogen

Patterson Companies

Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how NEOG, PDCO and DH are poised ahead of their earnings release.

3 Medical Product Stocks Set to Outpace Q2 Earnings Estimates

Definitive Healthcare Corp. (DH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Definitive Healthcare Corp. (DH) Beat Estimates Again in Its Next Earnings Report?

FRAMINGHAM, Mass. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced selected preliminary financial results for the quarter ended June 30, 2023.

Definitive Healthcare Reports Preliminary Financial Results for Second Quarter Fiscal Year 2023, Reaffirms Full Year Guidance for Revenue and Adjusted EBITDA, and Announces Restatement of Previously Issued Financials

News for Definitive Healthcare Corp Stock (DH)